Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Jonathan C. Fox(Fluidigm (United States)), Keyur B. Shah(Amyloidosis Foundation), Mazen Hanna(Cleveland Clinic), James E. Hoffman(Sylvester Comprehensive Cancer Center), Steen Hvitfeldt Poulsen(Aarhus University Hospital), Simon Gibbs(Amyloidosis Foundation), Marianna Fontana(Amyloidosis Foundation), Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Pablo García‐Pavía(Universidad Francisco de Vitoria), Haolin Xu(Duke University), Laura Obici(University of Pavia), Martha Grogan(Mayo Clinic in Arizona), Daniel P. Judge(Medical University of South Carolina), Jyotsna Garg(Clinical Research Institute), Francesco Cappelli(National Institute of Optics), Uma Sinha(BridgeBio (United States)), Prem Soman(Amyloidosis Foundation), Frank W. Rockhold(Amyloidosis Foundation), José Nativi-Nicolau(Jacksonville College), Xiaofan Cao(Amyloidosis Foundation), Ahmad Masri(Oregon Health & Science University), Karen Chiswell(Amyloidosis Foundation)
Cited by 453
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k